Stock Taper 
OmniAb, Inc. provides innovative antibody discovery platforms using genetically engineered transgenic animals to enable development of next-generation therapeutics and bispecific antibodies.
OmniUltra is a pioneering in vivo platform launched in December 2025, utilizing transgenic chickens to discover novel therapeutic antibodies and peptides with ultralong CDRH3 domains for challenging targets.
OmniAb, Inc. announced it had entered into a definitive agreement for a private placement of over 21.25 million shares of its common stock, raising approximately $30 million in gross proceeds. The sale of shares at a price below recent trading levels led to concerns about shareholder dilution, causing a significant negative reaction in the stock price.
OmniAb launched its OmniUltra™ platform, the industry's first transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. This strategic technology launch is intended to expand OmniAb's reach into new markets and therapeutic applications, including peptide discovery, and to advance its leadership in antibody discovery technologies.
Bank of America Corp DE acquired a new stake in OmniAb, Inc. (NASDAQ: OABI) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 149,493 shares of the company's stock, valued at approximately $368,000. Bank of America Corp DE owned
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 CCCC | $3.02 | COMPARE |
 IVVD | $0.81 | COMPARE |
 IPHA | $1.63 | COMPARE |
 CDXS | $1.40 | COMPARE |
 TARA | $2.60 | COMPARE |
 IMDX | $3.52 | COMPARE |
 MIST | $0.78 | COMPARE |
 RANI | $0.78 | COMPARE |
